ArticleJournal of the American Academy of Dermatology2021
The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study.
Article in Journal of the American Academy of Dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Autoimmune Skin Diseases in the Era of COVID-19: Pathophysiological Insights and Clinical Implications.Microorganisms · 2025Review
- Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.Frontiers in immunology · 2025Article
- Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.Journal of cutaneous pathology · 2023Article
- Case Report: The many faces of bullous pemphigoid.Frontiers in immunology · 2023Article
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- Editorial: Autoimmune pre-disease.Frontiers in immunology · 2023Article
- Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.Dermatologic therapy · 2022Article
- Autoimmune bullous dermatoses associated with COVID-19 outbreak in Russian patients: a single case series.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Article
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- SARS-CoV-2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis.JAAD international · 2022Article
- COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.Dermatologic therapy · 2022Article
- Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician.Clinical, cosmetic and investigational dermatology · 2022Review
- COVID-19 outcomes in patients with autoimmune blistering disease.The British journal of dermatology · 2021Article
- Epidemiology of Pemphigus.JID innovations : skin science from molecules to population health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe burden of COVID-19 in patients with bullous pemphigoid (BP) and pemphigus is yet to be evaluated.
objectiveTo assess the risks of COVID-19 and COVID-19-associated hospitalization and mortality in patients with BP and pemphigus and to delineate determinants of severe COVID-19 illness among these patients.
methodsA population-based cohort study compared COVID-19 and its complications in patients with BP (n = 1845) and pemphigus (n = 1236) with age-, sex-, and ethnicity-matched control subjects.
resultsThe risks of COVID-19 (hazard rate [HR], 1.12; 95% confidence interval [CI], 0.72-1.73; P = .691) and COVID-19-associated hospitalization (HR, 1.58; 95% CI, 0.84-2.98; P = .160) was comparable between patients with BP and controls. The risk of COVID-19-associated mortality was higher among patients with BP (HR, 2.82; 95% CI, 1.15-6.92; P = .023). The risk of COVID-19 (HR, 0.81; 95% CI, 0.44-1.49; P = .496), COVID-19-associated hospitalization (HR, 1.41; 95% CI, 0.53-3.76; P = .499), and COVID-19-associated mortality (HR, 1.33; 95% CI, 0.15-11.92; P = .789) was similar in patients with pemphigus and their controls. Systemic corticosteroids and immunosuppressants did not predispose COVID-19-positive BP and pemphigus patients to a more severe illness. LIMITATIONS: Retrospective data collection.
conclusionsPatients with BP experience increased COVID-19-associated mortality and should be monitored closely. Maintaining systemic corticosteroids and immunosuppressive adjuvant agents during the pandemic is not associated with worse outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.